All Photos(1)

Documents

COA/COQ

444225

MMP-3 Inhibitor II

Name: MMP-3 Inhibitor II
Brand: MM

The MMP-3 Inhibitor II, also referenced under CAS 161314-17-6, controls the biological activity of MMP-3. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Synonym(s):

MMP-3 Inhibitor II, N-Isobutyl-N-(4-methoxyphenylsulfonyl)-glycylhydroxamic Acid, NNGH

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₃H₂₀N₂O₅S

CAS Number:

161314-17-6

Molecular Weight:

316.37

MDL number:

MFCD02179370

UNSPSC Code:

12352200

NACRES:

NA.77

Quality Level

100

Assay

≥98% (TLC)

form

solid

manufacturer/tradename

Calbiochem^®

storage condition

OK to freeze

color

white

solubility

DMSO: 30 mg/mL
ethanol: 8 mg/mL

shipped in

ambient

storage temp.

10-30°C

General description

A cell-permeable, potent inhibitor of human MMP-3 (stromelysin; K_i = 130 nM).

A potent and cell-permeable inhibitor of human MMP-3 (K_i = 130 nM).

Biochem/physiol Actions

Cell permeable: yes

Primary Target
human MMP-3

Product does not compete with ATP.

Reversible: no

Target K_i: 130 nM against human MMP-3

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Kato, N., et al. 2002. Genome Informatics13, 272.
MacPherson, L.J., et al. 1997. J. Med. Chem. 40, 2525.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Interleukin-1alpha treatment of meniscal explants stimulates the production and release of aggrecanase-generated, GAG-substituted aggrecan products and also the release of pre-formed, aggrecanase-generated G1 and m-calpain-generated G1-G2.

Angelika K Lemke et al.

Cell and tissue research, 340(1), 179-188 (2010-03-11)

Pro-inflammatory cytokines induce meniscal matrix degradation and inhibition of endogenous repair mechanisms, but the pathogenic mechanisms behind this are mostly unknown. Therefore, we investigated details of interleukin-1 (IL-1alpha)-induced aggrecan turnover in mature meniscal tissue explants. Fibro-cartilagenous disks (3 mm diameter